Global Multicancer Screening Market Size is valued at USD 2.3 Bn in 2024 and is predicted to reach USD 9.7 Bn by the year 2034 at a 15.4% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
The increasing incidence of cancer and the requirement for early diagnosis diagnostics, which make simple disease management possible and thereby reduce the death rate, are the main drivers of market revenue growth. 2020 saw about 10 million cancer-related deaths worldwide, making it the leading cause of death. The most frequent cancers in terms of new cases in 2020 were breast, lung, colon and rectum, prostate, skin, and stomach.
Consequently, there is a peak in demand for MCEDS as cancer incidence rises. Multi-Cancer Early Detection (MCED) testing, a minimally invasive technology, can identify malignancies from many organ sites with just one test, reducing the number of operations and saving time.
Large-scale R&D for the creation of MCED is another element boosting market revenue growth. For instance, research to identify and validate novel biomarker combinations that detect various malignancies early was initiated in Singapore on July 8, 2022. For instance, the biotechnology business MIRXES Ptr Ltd. disclosed that Project CADENCE had started following the signing of a memorandum of agreement (Cancer Detected Early can be Cured). This project is the first large-scale clinical research project of its kind in the world, and it will enable the development of a multi-cancer early detection test for up to nine cancers with a high incidence and mortality rate, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
The Multicancer Screening market is segmented on the basis of test type, technology, sample, method, cancer type, application, and end-user. Test type segment includes Laboratory Developed Tests (LDTs) and In-Vitro Diagnostics (IVDs). The technology segment includes Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies. By sample, the market is segmented into Tissue, Blood, Saliva, Buccal Swabs, and Others.
The method segment includes DNA, RNA, and Proteins. By cancer type, the market is segmented as Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types. Application segment covers Clinical and Research. By end user, the market is categorized into Hospitals, Diagnostic and Clinical Laboratories, Academic and Research Institutions, and Other End Users
With the majority of market revenue, the hospitals segment dominated the entire market. The prevalence of specialized medical professionals and healthcare workers who are involved in diagnosis and treatment is responsible for this segment's dominance. Hospitals are used as a platform to inform and raise public knowledge of various illnesses and ailments. The target audience knows very little about MCED, a new technology. As a result, hospitals examine asymptomatic people for several types to facilitate therapy.
Due to the fact that it offers testing for several cancers, the LDT category had the highest revenue share. Gene panels target the identification of hereditary malignancies, and rising public awareness of hereditary diseases is expediting demand for genetic testing that can identify cancers early and enhance patient survival rates.
In Europe, the use of multi-cancer early detection has expanded in industries including hospitals, labs, diagnostic centers, and other significant market developments. The global market expansion in Europe is anticipated to be encouraged by the rising population, which is linked to a greater vulnerability to cancer-related chronic diseases and the economical diagnosis of chronic diseases in rural areas.
The market has grown significantly as a result of the increasing number of instances in Europe. For instance, according to a 2019 article by Eurostat, among the EU Member States, Hungary and Croatia had the highest standardized death rates for cancer, each with at least 300 per 100 000 residents. Due to these reasons, the European Union has started and intensified its attention on regional multi-cancer early detection programs.
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 2.3 Bn |
|
Revenue forecast in 2034 |
USD 9.7 Bn |
|
Growth rate CAGR |
CAGR of 15.4% from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Test Type, Technology, Sample, Method, Cancer Type, Application, And End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock DX, Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Fulgent Genetics., Genecast Biotechnology Co., Ltd, Guardant Health, Inc., Illumina, Inc., Konica Minolta, Inc., Laboratory Corporation of America Holdings., Myriad Genetics, Inc., Tempus, and Thermo Fisher Scientific Inc. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Multicancer Screening Market Snapshot
Chapter 4. Global Multicancer Screening Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Application Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Test Type Estimates & Trend Analysis
5.1. by Test Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Test Type:
5.2.1. Laboratory Developed Tests (LDTs)
5.2.2. In-Vitro Diagnostics (IVDs)
Chapter 6. Market Segmentation 2: by Technology Estimates & Trend Analysis
6.1. by Technology & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Technology:
6.2.1. Next-Generation Sequencing (NGS)
6.2.2. Polymerase Chain Reaction (PCR)
6.2.3. Immunohistochemistry (IHC)
6.2.4. Fluorescence In-Situ Hybridization (FISH)
6.2.5. Other Technologies
Chapter 7. Market Segmentation 3: by Sample Estimates & Trend Analysis
7.1. by Sample & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Sample:
7.2.1. Tissue
7.2.2. Blood
7.2.3. Saliva and Buccal Swab
7.2.4. Others
Chapter 8. Market Segmentation 4: by Method Estimates & Trend Analysis
8.1. by Method & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Method:
8.2.1. DNA
8.2.2. RNA
8.2.3. Proteins
Chapter 9. Market Segmentation 5: by Cancer Type Estimates & Trend Analysis
9.1. by Cancer Type & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Cancer Type:
9.2.1. Breast and Gynecologic
9.2.2. Gastrointestinal
9.2.3. Endocrine
9.2.4. Genitourinary
9.2.5. Skin
9.2.6. Brain/Nervous System
9.2.7. Sarcoma
9.2.8. Hematological Malignancies
9.2.9. Lung
9.2.10. Head and Neck
9.2.11. Other Cancer Types
Chapter 10. Market Segmentation 6: by Application Estimates & Trend Analysis
10.1. by Application& Market Share, 2024 & 2034
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
10.2.1. Clinical
10.2.2. Research
Chapter 11. Market Segmentation 7: by End User Estimates & Trend Analysis
11.1. by End User & Market Share, 2024 & 2034
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User:
11.2.1. Hospitals
11.2.2. Diagnostic and Clinical Laboratories
11.2.3. Academic and Research Institutions
11.2.4. Other End Users
Chapter 12. Multicancer Screening Market Segmentation 9: Regional Estimates & Trend Analysis
12.1. North America
12.1.1. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.1.2. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.1.3. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.1.4. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.1.5. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.1.6. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.1.7. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.1.8. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.2. Europe
12.2.1. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.2.2. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.2.3. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.2.4. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.2.5. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.2.6. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.2.7. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.2.8. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.3. Asia Pacific
12.3.1. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.3.2. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.3.3. Asia-Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.3.4. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.3.5. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.3.6. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.3.7. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.3.8. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.4. Latin America
12.4.1. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.4.2. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.4.3. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.4.4. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.4.5. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.4.6. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.4.7. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.4.8. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.5. Middle East & Africa
12.5.1. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.5.2. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.5.3. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.5.4. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.5.5. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.5.6. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.5.7. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.5.8. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Agilent Technologies, Inc.
13.2.2. Atara Biotherapeutics, Inc.
13.2.3. Burning Rock DX
13.2.4. Danaher Corporation
13.2.5. Exact Sciences Corporation
13.2.6. F. Hoffmann-La Roche Ltd
13.2.7. Fulgent Genetics.
13.2.8. Genecast Biotechnology Co., Ltd
13.2.9. Guardant Health, Inc.
13.2.10. Illumina, Inc.
13.2.11. Konica Minolta, Inc.
13.2.12. Laboratory Corporation of America Holdings.
13.2.13. Myriad Genetics, Inc.
13.2.14. Tempus
13.2.15. Thermo Fisher Scientific Inc.
13.2.16. Other Prominent Players
Multicancer Screening Market By Test Type-
Multicancer Screening Market By Technology-
Multicancer Screening Market By Sample-
Multicancer Screening Market By Method -
Multicancer Screening Market By Cancer Type-
Multicancer Screening Market By Application -
Multicancer Screening Market By End User -
Multicancer Screening Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
